Biomarin Pharmaceutical Inc (BMRN)
112.00
+3.67 +3.39%
NASDAQ
Jun 3, 16:59
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 1.805B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 0.61 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 114.01M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 77.82% |
| Profit Margin (Quarterly) | 16.21% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 20.25B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 11.35 |
| PE Ratio | 183.61 |
| Price to Book Value | 6.251 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.2632 |
| Free Cash Flow (Quarterly) | -59.21M |
| Return on Equity | Upgrade |
View All BMRN News
News
-
WireHeadlineTime (ET)
-
PR Newswire06/03 08:30
-
Yahoo06/01 10:35
-
MT Newswires06/01 03:40
-
Yahoo06/01 01:30
-
SA Breaking News05/31 18:23
-
PR Newswire05/31 16:01
-
Yahoo05/29 11:40
-
Yahoo05/29 11:31
-
Yahoo05/27 15:03
-
Yahoo05/27 12:55
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 07/31/2020 16:30 EDT | Misc | Biomarin Pharmaceutical Inc Second Quarter Earnings Conference Call in 2020 |
| 07/31/2020 | Earnings | Biomarin Pharmaceutical Inc Second Quarter Earnings in 2020 Release |
| 05/27/2020 09:00 PDT | Misc | Biomarin Pharmaceutical Inc Annual General Meeting for 2019 |
| 04/30/2020 16:30 EDT | Misc | Biomarin Pharmaceutical Inc First Quarter Earnings Conference Call for 2020 |
| 04/30/2020 | Earnings | Biomarin Pharmaceutical Inc First Quarter Earnings Result for 2020 |
| 02/27/2020 | Misc | Biomarin Pharmaceutical Inc Annual Report for 2019 |
| 02/26/2020 16:30 EST | Misc | Biomarin Pharmaceutical Inc Fourth Quarter Earnings Conference Call for 2019 |
| 02/26/2020 | Earnings | Biomarin Pharmaceutical Inc Fourth Quarter Earnings in 2019 Release |
| 10/23/2019 16:30 EDT | Misc | Biomarin Pharmaceutical Inc Third Quarter Earnings Conference Call for 2019 |
| 10/23/2019 | Earnings | Biomarin Pharmaceutical Inc Third Quarter Earnings in 2019 Release |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.bmrn.com
- Investor Relations URL: http://investors.bmrn.com/
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Jul. 31, 2020
- Last Earnings Release: Apr. 30, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 112.00 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| BBH | VanEck Vectors Biotech ETF | 4.57% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.67% |
| VHCOX | Vanguard Capital Opportunity Inv | 3.26% |
| POAGX | PRIMECAP Odyssey Aggressive Growth | 2.19% |
| XBI | SPDR® S&P Biotech ETF | 2.15% |
| IBB | iShares Nasdaq Biotechnology ETF | 2.10% |
| POGRX | PRIMECAP Odyssey Growth | 2.00% |
| FXH | First Trust Health Care AlphaDEX® ETF | 1.80% |
| RAEBX | American Funds AMCAP R2E | 1.56% |
| FBIOX | Fidelity® Select Biotechnology | 1.45% |
| VEXMX | Vanguard Extended Market Index Investor | 0.39% |
| VXF | Vanguard Extended Market ETF | 0.39% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- BMRN Tweets Stocktwits
Advertisement
